On November 18, 2015 Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, OTCQX:ONCYF) reported that enrollment has commenced in a Phase Ib study of REOLYSIN combined with standard doses of bortezomib (Kyprolis) and dexamethasone in patients with relapsed or refractory multiple myeloma (REO 019) (Press release, Oncolytics Biotech, NOV 18, 2015, View Source [SID:1234508281]). Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University of Southern California (USC), is the principal investigator. Schedule your 30 min Free 1stOncology Demo! "We recently announced promising early results from another multiple myeloma study examining REOLYSIN in combination with carfilzomib," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our goal is to determine how REOLYSIN performs with the standard of care options in this difficult to treat indication and then take the best combination forward into later-stage testing."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study is a two-stage open-label Phase Ib trial of adult patients with relapsed or refractory multiple myeloma following at least one line of therapy. The study objectives include determining the maximum tolerated dose ("MTD") and the safety profile of REOLYSIN in combination with bortezomib and dexamethasone, as well as exploring the toxicities and the pharmacodynamics of the treatment combination, and determining the preliminary response rate in patients with relapsed or refractory multiple myeloma.
Adult patients will receive REOLYSIN on days 1, 2, 8, 9, 15 and 16 of each 28-day cycle. Patients will also receive bortezomib and dexamethasone on days 1, 8 and 15.The first stage of the study will enroll three to six patients in each of two cohorts, with each cohort at a different dose level. The second stage of the study will enroll up to 12 patients at the MTD reached in the first stage.
About Multiple Myeloma
Multiple Myeloma is a cancer of the plasma cells and the second most common hematological malignancy. The American Cancer Society estimates there will be 26,850 new cases diagnosed in the United States and 11,240 deaths from the disease in 2015.